ADA and tuberculosis: Compared to ADA (clinical cut-point 35 IU/ml) and clinical predictors, the biomarker uIFNγ (cut-point 44 pg/ml) offers better rule-in utility with higher sensitivity, LR+, and in high TB prevalence settings (prevalence = 50%) a PPV of 96.9% (95.1 to 98.1) [see Additional file 1: Table S5].